Cedarburg Hauser adds plant capacity

Wednesday, September 26, 2012 09:32 AM

Cedarburg Hauser Pharmaceuticals (CHP), a Grafton, Wisc.-based contract development and manufacturing organization, has expanded the capacity of its active pharmaceutical ingredient (API) manufacturing plant in Wisconsin.

The expansion efforts are a result of an increased demand for contract manufacturing of commercial APIs and are accompanied by additional upgrades aimed at improving safety and GMP systems.

“These improvements increase our total reactor capacity by nearly 50%,” said John Flahive, CHP’s newly hired director of operations. “We have also added a reactor and chiller that allow for cryogenic reactions in our GMP labs.”

In addition to the new reactors, CHP has also made improvements to the air handling systems in the GMP manufacturing suites, installed a reverse osmosis water system, improved isolation capabilities and upgraded their Emerson DeltaV Digital Automation System.

“The added reactor capacity and upgrades to existing safety and GMP systems are the latest example of Cedarburg Hauser’s continued commitment to serving the commercial API marketplace,” said Tony Laughrey, CEO of CHP. “The flexibility afforded by the additional reactor capacity allows us to better meet our customer’s on-time and on-budget requirements.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs